Navigation Links
SyntheMed Receives CE Mark Approval for REPEL-GYN™
Date:5/24/2010

ISELIN, N.J., May 24 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion products, today announced that REPEL-GYN™, the company's bioresorbable adhesion barrier film for the reduction of adhesions following gynecologic surgery, has received CE Mark approval in the European Union (EU).  CE Mark approval signifies that REPEL-GYN has met the essential requirements of the European Union Medical Devices Directive and enables the company to begin marketing the product to reduce the incidence, severity and extent of post-operative adhesion formation in patients undergoing gynecologic surgery.  

The formation of adhesions (scar tissue) between organs in the pelvic cavity is a frequent, undesirable result of gynecologic surgery.  Pelvic adhesions can cause the patient to endure chronic pain, small bowel obstruction and infertility.  The presence of adhesions is also a complicating factor in repeat caesarian sections.  There are an estimated 2 million gynecologic procedures performed annually in the EU and other international markets in which the patients are at risk of developing adhesion-related complications.

Robert P. Hickey, President and CEO, SyntheMed, Inc., stated, "We are very pleased to have received regulatory approval to expand the use of our proprietary bioresorbable polymer film in the EU markets.  REPEL-GYN is similar to REPEL-CV® Adhesion Barrier which is currently marketed internationally for use in all cardiac surgical procedures and in pediatric cardiac surgery in the United States.  We are currently evaluating our options on the marketing of REPEL-GYN throughout the EU either through a corporate partn
'/>"/>

SOURCE SyntheMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SyntheMed Receives Brazilian Regulatory Approval for REPEL-CV(TM)
2. SyntheMed Receives Russian Regulatory Approval for REPEL-CV(TM)
3. SyntheMed Receives US Patent on Novel Polymer Technology
4. SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination
5. SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
6. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
7. SyntheMed Announces FDA Clearance of SinusShield(TM)
8. SyntheMed Announces New Management Appointments
9. SyntheMed Completes $4.0 Million Equity Placement
10. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
11. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
(Date:8/20/2014)... 20, 2014 GraphDB™ 6.0 ... including improvements to the enterprise replication cluster, faster ... Lucene, SOLR and Elasticsearch. This release happens to ... performance triplestore – GraphDB™ was formerly known as ... the only mature enterprise resilient RDF triplestore will ...
(Date:8/19/2014)... , Aug. 19, 2014 A Geisinger ... been nominated for a Centers for Disease Control and ... a major public health concern. Joseph ... is one of a team of researchers nominated for ... C. Shepard Science Award for Data Methods and Study ...
(Date:8/19/2014)... 2014 XenoTech announces an exclusive ... metabolite production from bioactive small molecules. Based ... technology enables convenient and timely assessment of critical ... Vice President of Commercial Operations, Christian Darabant, “the ... risk can be measured directly by comparison with ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... pace for healthcare in the Philadelphia suburbs, with unique new capabilities ... ... technologies, IRVINE, Calif., Jan. 10 ... Pulse CO-Oximetry and,Read-Through-Motion & Low Perfusion Pulse Oximetry, have announced the,completion ...
... Alerts for key stocks., Seven Summits Strategic Investments, ... (Note: You may have to copy this link,into your ... Alerts cover the following stocks: Exxon Mobil Corp.,(NYSE: ... MER ), DryShips, Inc. (Nasdaq:,DRYS), Computer Sciences Corp. (NYSE: ...
... 10 Transgene,(Euronext Paris: FR0005175080) announces promising preliminary ... vaccine TG4010,(MVA-MUC1-IL2) as an adjunct to first line ... (NSCLC)., This on-going trial is a randomized, ... efficacy of TG4010 in combination with cisplatin and,gemcitabine ...
Cached Biology Technology:Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 2Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 3Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 4Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI 2Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI 3Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 2Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 3
(Date:8/19/2014)... It,s not a monkey. It,s not a lemur. It,s ... Meet the Philippine tarsier: a tiny, adorable and downright "cool" ... animals that Americans are familiar with," said Rafe Brown, curator-in-charge ... giant eyes and ears; an extremely cute, furry body; a ... interesting expanded fingers and toe tips that look a bit ...
(Date:8/19/2014)... born with neonatal abstinence syndrome (NAS) secondary to ... going through withdrawal than others, but the underlying ... epigenetic (when genes are turned on or off) ... researchers at Boston University School of Medicine (BUSM) ... of its kind study to identify some of ...
(Date:8/19/2014)... ever had a glass of fizzy soda knows that ... in a finding with wide industrial applications, Princeton researchers ... down into the liquid as well. , "It is ... we were surprised, and fascinated, to discover that when ... injected tiny oil droplets into the water," said Howard ...
Breaking Biology News(10 mins):Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3
... bacteria, and like any hardworking homeowner, they have developed ... Berkeley, biologists have found. , In a study of ... its roots, UC Berkeley researchers have shown that the ... than they do to the slackers. Root nodules - ...
... The risk of human bird flu infection is small in Australia ... according to bird medicine specialist Dr Bob Doneley. , "The ... neighbours birds are so infinitesimally small," UQ School of Veterinary Science ... have a light plane hit by a meteor and fall on ...
... now have access to one of the most advanced microscopes ... Facility, opened this fall, is a combination of an atomic ... commercial machine of its kind. , The atomic force microscope ... confocal microscope system by Olympus America Inc. Integration of the ...
Cached Biology News:Plants, too, have ways to manage freeloaders 2Plants, too, have ways to manage freeloaders 3Plants, too, have ways to manage freeloaders 4Expert dispels bird flu paranoia 2
... Trap Time of Flight Mass Analyzer for superior sensitivity, mass accuracy, ... - 25,000 m/z, * Precursor ion selection range: 150 - 4000 ... 5 ppm with internal reference, * Dynamic range: 4 orders of ... ...
... pYD1 Yeast Display Vector is specifically designed ... the surface of Saccharomyces cerevisiae. Displayed proteins ... interact with known or putative ligands. pYD1 ... consists of two domains, Aga1 and Aga2, ...
... Oncostatin M (OSM) is a pleiotropic ... and Kaposis sarcoma cells. OSM inhibits the ... lines, simulates fibroblast, smooth muscle and Kaposis ... cells and low density lipoprotein receptor expression ...
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
Biology Products: